Loading...
•
Dec 31, 2025
Corbus Pharmaceuticals Q4 2025 Earnings Report
Corbus Pharmaceuticals Q4 2025 Earnings Report
Key Takeaways
Corbus Pharmaceuticals reported a net loss of $20.6 million for Q4 2025 as it ramped up clinical development for its oncology and obesity pipelines. The company successfully extended its cash runway into 2028 following a $75 million public offering and reported positive early-stage data for its lead candidates CRB-701 and CRB-913.
Reported positive Phase 1/2 data for CRB-701 in HNSCC and cervical cancer with unconfirmed ORRs of 47.6% and 37.5% respectively.
CRB-913 Phase 1a data demonstrated 2.9% placebo-adjusted weight loss at 14 days with a favorable GI safety profile.
Completed a $75 million public offering in Q4 2025, strengthening the balance sheet to $163.3 million in total cash and investments.
Deprioritized the CRB-601 program following the completion of the Phase 1 dose escalation trial to focus resources on lead assets.
Forward Guidance
Corbus is focused on multiple clinical catalysts in 2026 across its ADC and obesity programs, supported by a cash runway extending into 2028.
Positive Outlook
- Cash runway expected to fund operations into 2028.
- Anticipated update in Q1 2026 regarding registrational study protocols for CRB-701.
- CRB-701 monotherapy durability data expected in mid-2026.
- CANYON-1 Phase 1b 12-week obesity study completion expected in summer 2026.
- CRB-701 + Keytruda combination data in 1L HNSCC expected in Q4 2026.
Challenges Ahead
- Operating expenses increased significantly due to higher clinical development costs.
- Net loss widened to $20.6 million in Q4 compared to $9.5 million in the prior year.
- CRB-601 program has been deprioritized with no further enrollment planned.
- Clinical success for lead assets is dependent on upcoming durability and dose-ranging data.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...